Occupational asthma

Press release - MEPs adopt new rules to limit exposure to harmful substances at the workplace

Retrieved on: 
Wednesday, February 7, 2024

MEPs adopt new rules to limit exposure to harmful substances at the workplace

Key Points: 
  • MEPs adopt new rules to limit exposure to harmful substances at the workplace
    - Rules for exposure to lead updated for the first time in 40 years
    - Limit values for diisocyanates for first time ever
    - Better protection for those working to ensure the green transition
    On Wednesday, Parliament adopted new exposure limit values for lead for the first time in forty years and for diisocyanates for the first time ever.
  • Both substances are widely used to renovate buildings and to produce batteries, wind turbines, and to make electric vehicle lighter.
  • By limiting their exposure to these chemicals, the EU is protecting those working in the green transition.
  • Past exposure to lead
    Some workers have been exposed to lead over several years and have accumulated blood-lead levels well above any new limit value.

Highlights - Better protecting workers from the risks related to asbestos and lead: votes - Committee on Employment and Social Affairs

Retrieved on: 
Friday, September 1, 2023

Better protecting workers from the risks related to asbestos and lead: votes

Key Points: 
  • Better protecting workers from the risks related to asbestos and lead: votes
    The committee on Employment and Social Affairs will vote both, on the agreement reached by Parliament and Council on the asbestos at work directive, as well as on on the legislation protecting workers from lead and diisocyanates at its meeting of 7 September 2023 (10:15 to 13:00).
  • The committee on Employment and Social Affairs will vote, on 7 September, on the agreement reached by Parliament and Council on the asbestos at work directive.
  • This directive calls on employers to reduce exposure to asbestos fibres to the lowest possible level and sets out a list of ways to avoid exposure.
  • The committee will also vote on the legislation protecting workers from lead and diisocyanates.

Worldwide Respiratory Protective Equipment Industry to 2027 - Featuring 3M, Alpha Pro Tech and Honeywell International Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, July 4, 2022

The respiratory protective equipment (RPE) refers to a kind of personal protective equipment (PPE) that safeguards the wearer from inhaling hazardous substances, dust particles and gases in the air.

Key Points: 
  • The respiratory protective equipment (RPE) refers to a kind of personal protective equipment (PPE) that safeguards the wearer from inhaling hazardous substances, dust particles and gases in the air.
  • These equipment are commonly used in chemicals, textiles and paper processing mills, along with metalworking plants and construction sites.
  • The competitive landscape of the industry has also been examined with some of the key players being 3M Company, Alpha Pro Tech Limited, E.D.
  • What is the structure of the global respiratory protective equipment market and who are the key players?

Global Asthma Epidemiology and Patient Flow Report 2021: Asthma Prevalence, Diagnosed, and Drug-treated Patients Forecast to 2035 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 13, 2021

The "Global Asthma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Asthma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Global Asthma Epidemiology and Patient Flow Analysis - 2021, provides Asthma epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Asthma patients, history of the disease at the population level (Asthma prevalence, Asthma incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Asthma patients by age group, gender
    The data from this research will help executives:
    Establish basis for Asthma market sizing, assessing market potential, and developing drug forecast models
    Identify Asthma patients segments through age groups, gender, and disease sub-types

New Tezepelumab Data Continue to Strengthen Profile for a Broad Population of Severe Asthma Patients

Retrieved on: 
Thursday, May 13, 2021

New trials are being planned to evaluate the ability of tezepelumab to reduce OCS use while maintaining asthma control in patients with chronic maintenance OCS therapy.

Key Points: 
  • New trials are being planned to evaluate the ability of tezepelumab to reduce OCS use while maintaining asthma control in patients with chronic maintenance OCS therapy.
  • Approximately 10% of asthma patients have severe asthma.
  • Despite the use of inhaled asthma controller medicine, currently available biologic therapies and OCS, many severe asthma patients remain uncontrolled.
  • Tezepelumab acts at the top of the inflammation cascade and has the potential to treat a broad population of severe asthma patients regardless of their type of inflammation.\nIn 2020, Amgen and AstraZeneca updated the 2012 collaboration agreement for tezepelumab.

American Lung Association to Reduce Asthma-related ER and Hospital Visits for Communities Most Burdened by Asthma

Retrieved on: 
Thursday, April 8, 2021

Without proper management of the disease, asthma symptoms can worsen and result in asthma attacks, emergency department and hospital visits.

Key Points: 
  • Without proper management of the disease, asthma symptoms can worsen and result in asthma attacks, emergency department and hospital visits.
  • In an effort to improve health and prevent asthma-related emergency department and hospital visits, especially for those most impacted, the American Lung Association is expanding its asthma intervention work with support from the Centers for Disease Control and Prevention (CDC).
  • The American Lung Association's Promoting Asthma Friendly Environments through Partnerships and Collaborations project received a five-year, $1 million cooperative agreement from the CDC's National Asthma Control Program.
  • The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research.

Aservo™ EquiHaler™, industry-first therapy for severe equine asthma, now available in Canada

Retrieved on: 
Tuesday, March 30, 2021

BURLINGTON, ON, March 30, 2021 /CNW/ - Boehringer Ingelheim Animal Health Canada Inc. has been granted marketing authorization for AservoEquiHaler, an inhaled therapy for horses with severe asthma.

Key Points: 
  • BURLINGTON, ON, March 30, 2021 /CNW/ - Boehringer Ingelheim Animal Health Canada Inc. has been granted marketing authorization for AservoEquiHaler, an inhaled therapy for horses with severe asthma.
  • While inhaled therapies for the treatment of asthma are common in human health, the Aservo EquiHalermarks an industry first in equine medicine in Canada.
  • Until now, there have been no approved inhalant therapies licensed for use in horses with equine asthma.
  • Equine asthma is often triggered by exposure to high concentrations of airborne dust particles, which leads to obstruction of the lower airways.

Tezepelumab Is the First Biologic to Consistently and Significantly Reduce Exacerbations in Broad Population of Severe Asthma Patients

Retrieved on: 
Friday, February 26, 2021

AstraZeneca is an established leader in respiratory care, and its inhaled and biologic medicines reached more than 53 million patients in 2019.

Key Points: 
  • AstraZeneca is an established leader in respiratory care, and its inhaled and biologic medicines reached more than 53 million patients in 2019.
  • Efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma: results from the phase 3 NAVIGATOR study.
  • The management of severe asthma: economic analysis of the cost of treatments for severe asthma.
  • Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma (DESTINATION) [Online].

DUPIXENT® (dupilumab injection) now approved by Health Canada for patients with severe asthma

Retrieved on: 
Tuesday, November 17, 2020

DUPIXENT is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins3and is not an immunosuppressant.

Key Points: 
  • DUPIXENT is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins3and is not an immunosuppressant.
  • "The daily management of asthma can be a significant burden for Canadians living with the disease.
  • It can be even more frustrating for those patients who are compliant with their Asthma Action Plan and medication, but their debilitating symptoms persist," says Vanessa Foran, President & CEO, Asthma Canada.
  • Severe Asthma.

Allergy & Asthma Network Secures PCORI Engagement Award, CDC Grant to Reduce COVID-19 and Asthma Disparities

Retrieved on: 
Wednesday, August 12, 2020

The Network has been awarded $150,000 through the Eugene PCORI Engagement Awards program.

Key Points: 
  • The Network has been awarded $150,000 through the Eugene PCORI Engagement Awards program.
  • "Many factors impact asthma health disparities, from income level and lack of health insurance to increased exposure to environmental allergens and irritants," says Tonya Winders, President and CEO of Allergy & Asthma Network.
  • EXHALE's patient-centered strategies are designed to reinforce asthma self-management, reduce exposure to asthma triggers, improve access and adherence to medications, and reduce healthcare costs.
  • Allergy & Asthma Network is the leading national nonprofit organization dedicated to ending needless death and suffering due to asthma, allergies and related conditions.